{"schema_version":"1.0","type":"article","title":"禮來口服藥引爆市場？","url":"https://drugnews.com.tw/articles/2026-04-21-dcard-261339270.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-21-dcard-261339270.md","lang":"zh-Hant","date":"2026-04-21","publish_at":"2026-04-21T10:30:00+08:00","updated_at":"2026-04-21","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI","GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年 4 月，Eli Lilly 的 Foundayo（orforglipron） 獲 FDA 核准，用於成人肥胖，或合併體重相關共病的過重族群。","key_points":[],"facts":[],"sections":["Orforglipron 引爆口服減重藥第二戰場：狂歡背後，真正的考題才剛開始","🔹 口服減重藥，不只是更方便而已","💡 市場邊界，會因為口服劑型而被直接打開","⚠️ 真正的風險，不只在副作用，也在錯誤使用","🧭 非肥胖者也在用藥，是否代表市場其實被高估了？","📌 口服化，會把這個矛盾推得更明顯","⏳ 真正更難的，其實是長期使用","🚀 第二戰場已經開打，而且不只 Lilly 一家","🌍 真正的考題，現在才剛開始"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"FDA Approves First New Molecular Entity Under National Priority Voucher Program","source":"FDA","date":"","url":""},{"title":"The U.S. Food and Drug Administration today approved Foundayo (orforglipron) marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program.","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"\"FDA Approves First New Molecular Entity Under National Priority Voucher Program","source":"FDA\"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"\"FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions","source":"Eli Lilly and Company\"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"Patterns and predictors of self-medication behavior of weight loss medications: a cross-sectional analysis of social media influence and role of pharmacist intervention","source":"","date":"","url":""},{"title":"Findings highlight a growing trend of social media-driven decisions regarding weight-loss medication use and the associated risks of unregulated online-purchases. Pharmacists play a crucial role in mitigating adverse outcomes by promoting drug safety and","source":"","date":"","url":""},{"title":"pubmed.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"\"a cross-sectional analysis of social media influence and ...\"","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"JMIR Formative Research - Quality Assessment of Medical Institutions’ Websites Regarding Prescription Drug Misuse of Glucagon-Like Peptide-1 Receptor Agonists by Off-Label Use for Weight Loss: Website Evaluation Study","source":"","date":"","url":""},{"title":"Background: Misuse of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has emerged globally as individuals increasingly use these drugs for weight loss because of unrealistic and attractive body images advertised and shared on the internet. Objective:","source":"","date":"","url":""},{"title":"formative.jmir.org","source":"","date":"","url":""},{"title":"\"JMIR Formative Research - Quality Assessment of Medical Institutions’ Websites Regarding Prescription Drug Misuse of Glucagon-Like Peptide-1 Receptor Agonists by Off-Label Use for Weight Loss: Website Evaluation Study\"","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"HTTP Status 404 – Not Found","source":"","date":"","url":""},{"title":"https://journals.plos.org/globalpublichealth/article/file","source":"","date":"","url":"https://journals.plos.org/globalpublichealth/article/file"},{"title":"journals.plos.org","source":"","date":"","url":""},{"title":"id=10.1371%2Fjournal.pgph.0005516&type=printable \"Beyond the prescription: Global observations on the social implications of GLP-1 receptor agonists for weight loss\"","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"WHO issues global guideline on the use of GLP-1 medicines in treating obesity","source":"","date":"","url":""},{"title":"To address the growing global health challenge of obesity, which affects more than 1 billion people, WHO has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.","source":"","date":"","url":""},{"title":"www.who.int","source":"","date":"","url":""},{"title":"\"WHO issues global guideline on the use of GLP-1 medicines in treating obesity\"","source":"","date":"","url":""},{"title":"[7]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-requires-lilly-conduct-post-marketing-studies-obesity-pill-2026-04-14/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-requires-lilly-conduct-post-marketing-studies-obesity-pill-2026-04-14/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[8]:","source":"","date":"","url":""},{"title":"Eli Lilly and Company - 716485 - 09/09/2025","source":"FDA","date":"","url":""},{"title":"False & Misleading Claims/Misbranded","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"\"Eli Lilly and Company - 716485 - 09/09/2025","source":"FDA\"","date":"","url":""},{"title":"[9]:","source":"","date":"","url":""},{"title":"Novo Nordisk to advance subcutaneous and oral amycretin for","source":"","date":"","url":""},{"title":"Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight...","source":"","date":"","url":""},{"title":"www.globenewswire.com","source":"","date":"","url":""},{"title":"\"Novo Nordisk to advance subcutaneous and oral amycretin for\"","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：禮來口服藥引爆市場？（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261339270/dcard-01.webp"},{"alt":"Dcard 原圖：禮來口服藥引爆市場？（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261339270/dcard-02.webp"},{"alt":"Dcard 原圖：禮來口服藥引爆市場？（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261339270/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261339270/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-21）。禮來口服藥引爆市場？。https://drugnews.com.tw/articles/2026-04-21-dcard-261339270.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-21-dcard-261339270-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}